Hospital denies that withdrawal of MD's job offer was related to drug-company funding

Silversides, Ann
June 2001
CMAJ: Canadian Medical Association Journal;6/26/2001, Vol. 164 Issue 13, p1879
Academic Journal
Reports that Toronto's Centre for Addiction and Mental Health (CAMH) and the University of Toronto withdrew a job offer to Dr. David Healy because of his views on fluoxetine. Argument of Healy that the pharmaceutical company Eli Lilly has an obligation to conduct a clinical trial in order to better determine which patients are best suited to receive the drug; Financial support which the company has provided to CAMH.


Related Articles

  • Star veteran joins Lilly PR team.  // Indianapolis Business Journal;5/7/2001, Vol. 22 Issue 8, p6 

    Reports the selection of Dennis Royalty as the senior communications associate of Eli Lilly and Co. in Indianapolis, Indiana. Educational attainment of Royalty; Career history; Views of Royalty on the business capability of Eli Lilly.

  • Born-Again Prozac: Not Worth the Extra Cost. Napoli, Maryann // HealthFacts;Jul2001, Vol. 26 Issue 7, p1 

    Announces the move of Eli Lilly company to release a repackaged version and a new dosage form of its antidepressant drug Prozac in the United States.

  • Lilly will boost Prozac spending.  // Indianapolis Business Journal;02/02/98, Vol. 18 Issue 47, p5 

    Discloses Eli Lilly & Co.'s plans to spend $40 million to $60 million into direct consumer advertising for its antidepressant, Prozac. Nine percent sales increase in fiscal 1997; Revenue losses experienced in fiscal 1997; Operating income increase for fiscal year 1997.

  • Eli Lilly's Prozac heads toward $3 billion barrier. Andrews, Greg // Indianapolis Business Journal;2/5/96, Vol. 16 Issue 47, p3A 

    Reports on the projected sales of Eli Lilly and Co.'s Prozac brand of antidepressant. Sales in 1995; Competitors.

  • Study calls Prozac safe for use during pregnancy.  // Indianapolis Business Journal;01/27/97, Vol. 17 Issue 46, p18A 

    Reports that a study has found that Eli Lilly and Co.'s antidepressant Prozac does not pose any risks to unborn children when taken by pregnant mothers. Applicability of the study to other antidepressants known as tricyclics; Drugs' lack of effects on children's behavior, IQ, and their ability...

  • Prozac Sales are Upbeat; Rise 12 Percent In Quarter. Jefferson, Greg // Indianapolis Business Journal;10/26/98, Vol. 19 Issue 32, p6A 

    Reports on an increase in the sales of antidepressant drug Prozac during the third quarter of 1998 for Indianapolis, Indiana-based Eli Lilly and Co. Growth in the domestic sales revenue of the drug; Overall increase in the sales revenue of the pharmaceutical sector in Indianapolis during the...

  • Lilly Makes Cuts, Aims To Speed R&D.  // Chain Drug Review;9/28/2009, Vol. 31 Issue 16, p58 

    The article reports on the announcement by U.S.-based Eli Lilly and Co. to reduce its worldwide work force by 14 percents by the end of 2011. Such plan aims to reduce 1 billion dollars in costs while the patents for its bestselling drug called Prozac will expire. John Lechleiter, chairman and...

  • Prozac Getting a New Prescription. Hume, Scott // Adweek Midwest Edition;09/21/98, Vol. 39 Issue 38, p5 

    Reports on direct-to-consumer television advertising of the Prozac prescription antidepressant by Eli Lilly and Co., in the pharmaceutical industry in the United States. Description of the advertisement; Cost of advertising; Background information on Prozac.

  • Sepracor, Eli Lilly Terminate R-Fluoxetine Agreement.  // Chemical Market Reporter;10/23/2000, Vol. 258 Issue 17, p14 

    Reports on the decision of Eli Lilly & Co. to stop clinical development for a single-enantiomer version of its best-selling drug Prozac (flouxetine). Reason behind the decision; Sales of Prozac in 1999; How Lilly will reposition its anti-depressant franchise.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics